VSV

Authentic Raises Over $5M to Tech-Enable Captive Insurance

Retrieved on: 
Mercoledì, Settembre 20, 2023
Insurance, MGV, Software as a service, Organizational founder, VSV, Attention, Organization, Running, Risk, Engineering, Authenticity

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Authentic, the "captive in a box" insurance platform announces the close of a $5.5m seed financing. The round was led by Slow Ventures with participation from MGV, Altai, Clocktower, Commerce Ventures, Mischief Ventures, Core Innovation Capital, and Upper90 in addition to a number of insurance executives. Authentic makes it possible for any SaaS company, association, franchisor, or roll-up to monetize insurance with no integration work.

Key Points: 
  • NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Authentic , the "captive in a box" insurance platform announces the close of a $5.5m seed financing.
  • Authentic makes it possible for any SaaS company, association, franchisor, or roll-up to monetize insurance with no integration work.
  • Authentic compresses all of the insurance complexity associated with captive insurance and delivers a turnkey platform for distribution partners.
  • Start your own turnkey captive insurance company with Authentic!

CPG Food & Beverage Industry Veteran Mike Murray Joins Good Karma Foods as Chief Executive Officer

Retrieved on: 
Lunedì, Dicembre 19, 2022
Karma, Coffee, Vitamin, Food technology, The Good Food Institute, Food industry, Partnership, Love, Knowledge, Growth, Animal, Nutrient, Good Karma, VSV, Pinterest, Food, CPG, Good Karma Brands, Strategy, Yoy, Plant, Retail

BOULDER, Colo., Dec. 19, 2022 /PRNewswire-PRWeb/ -- Good Karma Foods, a leading producer of nourishing plant-based milk and dairy alternatives, today announced that Mike Murray, a values-driven CPG food and beverage industry veteran known for leading high-growth brands, has joined the company as Chief Executive Officer (CEO). The addition of Murray to the Good Karma team coincides with a new round of funding that will accelerate growth for the innovative plant-based brand.

Key Points: 
  • BOULDER, Colo., Dec. 19, 2022 /PRNewswire-PRWeb/ -- Good Karma Foods , a leading producer of nourishing plant-based milk and dairy alternatives, today announced that Mike Murray, a values-driven CPG food and beverage industry veteran known for leading high-growth brands, has joined the company as Chief Executive Officer (CEO).
  • The addition of Murray to the Good Karma team coincides with a new round of funding that will accelerate growth for the innovative plant-based brand.
  • Murray joins the Good Karma team with more than 25 years of CPG experience, consistently leading brands that do real good for people, animals and the planet.
  • Prior to Teton Waters Ranch, Murray held executive and leadership roles at other values-focused organizations including free2b Foods, So Delicious Dairy Free, WhiteWave Foods Company and LARABAR.

Aescape Announces $30M Series A to Transform the Massage Therapy Experience

Retrieved on: 
Mercoledì, Novembre 16, 2022
Alternative Medicine, Professional Services, Health, Other Health, Fitness & Nutrition, Finance, General Health, Fitbit, Food technology, Crosslink Capital, Trinity Health, Blue Arc, Toll Brothers, Lachlan Power, Safety, Pandora, Growth, Host Hotels & Resorts, New York Knicks, Lowe's, BNP Paribas Real Estate, Silicon Valley Bank, Investment, Equinix, AV, Partnership, CBRE, ISPA, Research, VC, MGM Resorts International, LP record, Massage, Robotics, Kimco Realty, Food, VSV, Prince Harry, Duke of Sussex, Cushman & Wakefield, Meta, Marriott International, Cross-link, Uber, NBA, Courage, Pitch, Starwood Capital Group, SpaceX, WPP, Tower Research, The Related Companies, Wall, Security (finance), Management, Bank, Lennar Corporation, Chime, Tumblr

With this Series A funding, the company will enhance its AI-powered technology and bring The Aescape Experience to the U.S. market in 2023.

Key Points: 
  • With this Series A funding, the company will enhance its AI-powered technology and bring The Aescape Experience to the U.S. market in 2023.
  • After a seismic shift in the industry, the company created The Aescape Experience to help fill the widening labor shortage and booming demand for massage therapy.
  • Upon launch, The Aescape Experience is anticipated to transform the massage experience for hospitality, wellness and fitness industries, in addition to providing intuitive solutions and services for the $17.6B US massage therapy industry .
  • We're grateful to our investors for believing in our dream, and we look forward to launching The Aescape Experience in 2023.

Vyriad, Inc. Appoints Scott Beck as Chief Operating Officer

Retrieved on: 
Martedì, Settembre 13, 2022
Therapy, Time, University, Company, National Health Laboratory Service, COO, Measles, Patient, MBA, VSV, Leadership, Biotechnology, Mayo Clinic, PD-1, Dove Medical Press, Cancer, Regeneron Pharmaceuticals, Disease, Recurrence, Pharmaceutical industry

ROCHESTER, Minn., Sept. 13, 2022 /PRNewswire/ -- Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announces the appointment of Scott Beck, MBA as Chief Operating Officer.

Key Points: 
  • ROCHESTER, Minn., Sept. 13, 2022 /PRNewswire/ -- Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announces the appointment of Scott Beck, MBA as Chief Operating Officer.
  • During the past three decades Mr. Beck held many leadership roles at Mayo Clinic, covering multiple aspects of the discovery, translation and application of novel biotechnologies, and their commercial development.
  • He played a major part in the early development of the oncolytic virotherapy platforms licensed to Vyriad.
  • His proven leadership and relentless focus on execution will help realize our Company's goals," said Dr. Stephen Russell, Vyriad's Chief Executive Officer.

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

Retrieved on: 
Martedì, Settembre 6, 2022
U.S. Department of Commerce Office of Security, Spleen, Public health, Human, Food, RNA, Safety, National Institute, NYSE, Program, Research, Government, Liver, Sierra Leone, Infection, Vaccine, Disease, Solution, Feces, Risk, SVP, LinkedIn, CEPI, National Institute of Allergy and Infectious Diseases, VSV, NIH, SEC, RATS, EBS, National Institutes of Health, Coalition for Epidemic Preparedness Innovations, National, Emergent BioSolutions, Lassa fever, GLOBE, Office of Inspector General, U.S. Department of Health and Human Services, Emergent, Instagram, Lassa mammarenavirus, Yale University, Therapy, Emergency, Twitter, NIAID, Nursing, Knowledge, Marketing, Licensure, Open access, Private Securities Litigation Reform Act, Urine, Life, Pharmaceutical industry

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.

Key Points: 
  • GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.
  • This Phase 1 study, a randomized, placebo-controlled, dose-escalation study, will evaluate the safety and immunogenicity of Emergents rVSV-vectored Lassa virus vaccine in approximately 36 healthy adults at the Navrongo Health Research Centre and Kintampo Health Research Centre in Ghana.
  • Lassa virusa single-stranded RNA virus belonging to the family Arenaviridaecan cause the acute viral hemorrhagic illness known as Lassa fever.
  • In 2018, Emergent acquired development rights to the Profectus Lassa vaccine candidate now named EBS-LASV.

Hectagon to Launch TGE on August 8 Aiming to Bootstrap Decentralized VC DAO

Retrieved on: 
Lunedì, Agosto 8, 2022
TGE, Growth, VC, Forbes, Blockchain, Capital, Impact Hub (Global Network), Hectogon, UTC, Mistletoe, VSV, Venture capital, Cryptocurrency, Security (finance), Web3, Web 2.0

Hectagon is a novel platform that lets regular users get the windfall from investing into crypto startups at an early stage.

Key Points: 
  • Hectagon is a novel platform that lets regular users get the windfall from investing into crypto startups at an early stage.
  • The TGE for HECTA will launch on August 8 between 11:00 and 14:00 UTC.
  • Hectagon is made by the founders of VSV Capital , a Vietnam-based accelerator and VC that invested in over 80 startups, primarily in Web2.
  • Hectagon offers this opportunity, with the lineup of project pipeline, clear plan of making investment decisions by holding HECTA tokens in the Hectagon treasury.

Profitable Digital Health Platform Healthie Closes on $16M to Enable the Next Generation of Healthcare Delivery

Retrieved on: 
Martedì, Luglio 19, 2022
Healthy San Francisco, Ecosystem, University, Health information management, Autograph, Patient, Solution, Overalls, Payment Card Industry Data Security Standard, CMO, EToro, GLOBE, Technology, Compliance, Privacy, Organization, Industry, Wheel, Bureau of Primary Health Care, HIPAA, Growth, Builder, Health, API, VSV, Movement, Pharmaceutical industry, Online shopping, Techstars

Healthies scalable platform supports digital health companies rapid growth while also improving the patient experience and overall health outcomes.

Key Points: 
  • Healthies scalable platform supports digital health companies rapid growth while also improving the patient experience and overall health outcomes.
  • As digital health has exploded, Healthie is powering an overall movement to digital and virtual-first care delivery across the industry, says Healthie Co-Founder and CEO Erica Jain.
  • This funding allows us to strengthen the platform on which thousands of digital health companies are building their customer experiences.
  • Healthcare is undergoing a major disruption, and Healthie is a foundational piece of technology for thousands of innovative digital health companies and startups.

Valor Siren Ventures II Closes $595M Fund

Retrieved on: 
Mercoledì, Luglio 13, 2022
Technology, Retail, Food Tech, Entrepreneur, Finance, Consumer, Small Business, Online Retail, Restaurant, Bar, Professional Services, Environment, Other Retail, Sustainability, Food, Beverage, Food technology, Leadership, Valor, Alsea, Food, Vista Equity Partners, Gordon Food Service, Starbucks, Investment, VSV, SBUX, Company, Kirkland & Ellis, NASDAQ

Valor Equity Partners announced the completion of its oversubscribed fundraise on April 1, 2022 for Valor Siren Ventures II L.P. (VSV II), building upon the success of Valor Siren Ventures I L.P. (VSV I).

Key Points: 
  • Valor Equity Partners announced the completion of its oversubscribed fundraise on April 1, 2022 for Valor Siren Ventures II L.P. (VSV II), building upon the success of Valor Siren Ventures I L.P. (VSV I).
  • VSV Is strategic anchor investors, Starbucks Corporation (NASDAD: SBUX) and Nestl S.A. (NASDAQ: NSRGY), continued their support of Valor Siren Ventures mission with strategic anchor investments in VSV II.
  • We are incredibly grateful to be trusted and backed again by Starbucks and Nestl, two iconic companies in the food, beverage and retail industry, said Jon Shulkin, Valor Siren Ventures Fund Manager, Valor Partner, and Co-President of the Firm.
  • Kirkland & Ellis LLP served as legal advisor to Valor Equity Partners in connection with VSV II.

Superfly, Autograph.io and Velvet Sea Ventures Partner to Reimagine Festivals

Retrieved on: 
Martedì, Luglio 12, 2022
Technology, IRL, Van Gogh immersive experiences, Drum, NBCUniversal, Pixel, Sport, JDS, Marketing, JD Sports, CEO, GLOBE, Verizon Media, FRIENDS, Superfly, Partnership, Culture, Friends, Creativity, Non-fungible token, Fourth Arts Block, Citigroup, Aglet, Intel, Instagram, Music, NFT, Advisory board, Autograph, Creative, Commerce, ESPN, EToro, Investment, X, Collection, VSV, Twitter, Tourism, Creative industries, Entertainment, Facebook, Bonnaroo Music Festival

Each SUPERPASS NFT represents one vote in these creative decisions about the SUPERF3ST event, along with access to festivals and live events.

Key Points: 
  • Each SUPERPASS NFT represents one vote in these creative decisions about the SUPERF3ST event, along with access to festivals and live events.
  • Superfly founder Rick Farman, Velvet Sea Ventures partner Michael Lazerow and Autograph Chief Operating Officer and Chief Business Officer, Ted Russell, will serve on the companys board of directors.
  • Current Velvet Sea Ventures portfolio companies include Scopely, eToro, Liquid Death, LeoLabs, Autograph, Strigo, SuperRare, Elementus, and Pixel Vault.
  • Spanning private equity and venture capital, select investments include: SLAM, Autograph, Dibbs, Buzzer, Aglet, round21, Framework Ventures, and more.

RIT scientist receives NIH grant to study viruses with potential to treat prostate cancer

Retrieved on: 
Giovedì, Giugno 23, 2022
Rochester, Patient, Biomedical sciences, Hospital, Prostate cancer, Student, List of life sciences, National, Neoplasm, Hope, Rochester Institute of Technology, University, Technology, College, Associate, Cell, Research, NIH, Morris, Algorithm, Degenerative disease, RIT, Biotechnology, VSV, Outline of health sciences, Cancer, Rochester General Hospital, Recombinant vesicular stomatitis virus vaccines, Vaccine

ROCHESTER, N.Y., June 23, 2022 /PRNewswire-PRWeb/ -- The National Institutes of Health are funding Rochester Institute of Technology scientists to explore vesicular stomatitis virus's (VSV) potential for treating prostate cancer. Associate Professor Maureen Ferran from the Thomas H. Gosnell School of Life Sciences secured a three-year, $451,718 Research Enhancement Award (R15) grant from the NIH to investigate prostate cancer cells' susceptibility to the virus.

Key Points: 
  • The National Institutes of Health are funding Rochester Institute of Technology scientists to explore vesicular stomatitis virus's (VSV) potential for treating prostate cancer.
  • ROCHESTER, N.Y., June 23, 2022 /PRNewswire-PRWeb/ -- The National Institutes of Health are funding Rochester Institute of Technology scientists to explore vesicular stomatitis virus's (VSV) potential for treating prostate cancer.
  • Associate Professor Maureen Ferran from the Thomas H. Gosnell School of Life Sciences secured a three-year, $451,718 Research Enhancement Award (R15) grant from the NIH to investigate prostate cancer cells' susceptibility to the virus.
  • The researchers are comparing cells derived from prostate cancer patients where VSV successfully killed the cells and comparing them to cells from prostate cancer patients that were VSV-resistant.